| Leukemia |
ACTRN12613000358741: Azacitidine use in elderly patients (over 65) with high risk myelodysplasia/acute myeloid leukaemia. |
|
|
| Not yet recruiting | 4 | 40 | | | Illawarra Private Cancer Care Centre, Southern Haematology and Cancer Research Institute | myelodysplasia, acute myeloid leukaemia | | | | |
| Not yet recruiting | 4 | 128 | | | Cairns Hospital , QLD health- Clinical research fellowship | Follicular lymphoma, Chronic Lymphocytic Leukaemia | | | | |
ACTRN12614000158662: Prevention of oral mucositis in pediatric patients with acute lymphoblastic leukemia undergoing chemotherapy: a randomized controlled, cross-over trial using 0.12% chlorhexidine gluconate and 1% povidone iodine mouthwash |
|
|
| Recruiting | 4 | 20 | | | Amanda Christina C. Dujua, MD, Amanda Christina C. Dujua, MD
| oral mucositis, leukemia | | | | |
ChiCTR-ONRC-12002956: Imatinib Combined with Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation versus Imatinib Alone for Chronic Myeloid Leukemia in Chronic Phase |
|
|
| Completed | 4 | 150 | | imatinib combined with reduced-intensity allogenei ;imatinib alone | the First Affiliated Hospital of Zhejiang University School of Medicine; Level of the institution：, National Natural Science Foundation of China | chronic myeloid leukemia | | | | |
ChiCTR-OPC-15006896: The clinical study of initial induced remission failure in elderly patients with acute myeloid leukemia treated by HCAG/IA in combination with decitabine |
|
|
| Not yet recruiting | 4 | 50 | | D-IA ;D-HCAG | Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Institute of Hematology; Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine, QILU pharmaceutical co.,Ltd. | acute myeloid leukima | | | | |
ChiCTR2200060751: The safety and efficacy of dasatinib 50mg as first-line treatment in newly diagnosed CML-CP patients |
|
|
| Not yet recruiting | 4 | 107 | | dasatinib 50 mg qd PO | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, NA | Chronic myeloid leukemia | | | | |
2005-004211-30: Penicillin G and an aminoglycoside versus meropenem as initial empiric antibiotic therapy in lymphoma and leukemia patients with febrile neutropenia |
|
|
| Ongoing | 4 | 250 | Europe | Benzylpenicillin, benzylpenicillin, Tobramycin, Gentamicin, Netilmicin, Meropenem, Intravenous infusion, Benzylpenicillin, Penicillin, Nebcina, Garamycin, Gensumycin, Netilyn, Meronem | The Norwegian Radium Hospital | Lymphoma and leukemia patients with febrile neutropenia | | | | |
| Completed | 4 | 600 | | HAA regimen: Hom 2mg/m2 im or ivgtt qd day 1-7, Acla 20mg ivgtt qd day 1-7, Ara-C 100 mg/ m2 ivgtt, day 1-7 ;HAD regimen: Hom 2mg/m2 im or ivgtt qd day 1-7 DNR 40mg/m2 iv qd day 1-3 Ara-C 100mg/m2 ivgtt, day 1-7 ;DA regimen: DNR 40 mg/ m2 iv qd day1-3; Ara-C 100 mg/ m2 ivgtt, day 1-7 | Ruijin Hospital affiliated to Shanghai Jiaotong University Medical College; The Ministry of Science and Techonology of the People’s Republic of China, The Ministry of Science and Techonology, China | Acute myelocytic leukemia (AML) | | | | |
| Completed | 4 | 105 | | Analyze the related gene and protein samples of the patients without tumor in vitro and no intervention in vivo ;Analyze the related gene and protein samples of the patients in vitro and no intervention in vivo ;Detect the differences of genes and proteins after the inducement or intervention on leukemic cells with drugs | Beijing Children's Hospital Affiliated to Capital Medical University; Ministry of Science and Technology of the People's Republic of China, Ministry of Science and Technology of the People's Republic of China | Acute lymphocytic leukemia in children | | | | |
ChiCTR-TNC-09000397: A study of diagnosing and combination treatment of acute lymphoblastic leukemia in adult |
|
|
| Completed | 4 | 450 | | General clinical treatment | Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science; Ministry of Science and Technique, P. R. China, National Science and Technique Support Project | Acute lymphoblastic leukemia | | | | |
2010-022260-12: Antibiotic Therapy for early stage chronic lymphocytic leukaemia |
|
|
| Ongoing | 4 | 180 | Europe | Metronidazole, Clarithromycin, Ciprofloxacin, Lansoprazole, Omeprazole, Tablet, Capsule | King's College Hospital NHS Foundation Trust, King's College Hospital NHS Foundation Trust | Chronic Lymphocytic Leukaemia, Chronic Lymphocytic Leukaemia, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-OCH-11001831: Unmanipulated, related, haploidentical transplantation can achieve comparable outcomes to identical sibling transplantation for pediatric patients with high-risk acute leukemia |
|
|
| Completed | 4 | 181 | | related haplo-HSCT | People's Hospital Peking University; People's Hospital Peking University, National Science & Technology Pillar Program; National Natural Science Foundation of China | hematological malignancies | | | | |
ChiCTR-TNC-12001999: Clinical study of decitabine together with aclacinomycin/cytarabine to treating patients with refractory acute myeloid leukemia |
|
|
| Completed | 4 | 20 | | Aclacinomycin /Cytarabine (AA) | Shanghai Sixth People‘s Hospital; Shanghai Sixth People‘s Hospital, research funding | refractory/relapsed de nove or myelodysplastic syndrome (MDS) transformed acute myeloid leukemia (AML) | | | | |
ChiCTR-TRC-11001475: FA regimen as the consolidation chemotherapy in treatment of acute myeloid leukemia (AML): a multi-center, randomised clinical trial |
|
|
| Completed | 4 | 360 | | Fludarabine 30mg/ m2, intravenously administration daily for 3 days; Cytarabine 2g/ m2,intravenously administration daily for 3 days, 6 cycles in total ;Fludarabine 30mg/ m2, intravenously administration daily for 5 days; Cytarabine 1g/ m2,intravenously administration daily for 5 days, 6 cycles in total ;Fludarabine 30mg/ m2, intravenously administration daily for 5 days; Cytarabine 2g/ m2,intravenously administration daily for 5 days, 4 cycles in total | Chinese anti-cancer association; Chinese anti-cancer association, self-funding | acute myeloid leukemia (AML) | | | | |
2008-003012-35: CLARET: CLL Levels following Alemtuzumab in Responders to Early Therapy: A randomised, phase III trial to assess alemtuzumab consolidation therapy in patients with chronic lymphocytic leukaemia (CLL) who have responded to previous therapy. |
|
|
| Ongoing | 4 | 116 | Europe | Alemtuzumab (MabCampath), Concentrate for solution for injection, Concentrate for solution for infusion, MabCampath | Leeds Teaching Hospitals NHS Trust | Chronic lymphocytic leukaemia (CLL). | | | | |
ChiCTR-TRC-09000504: Therapeutic role of homoharringtonine in acute promyelocytic leukemia, an open label randomised controlled trial |
|
|
| Completed | 4 | 100 | | Induction therapy with combination of arsenic trioxide and homoharringtonine. After achieved CR, patients receive consolidation treatment with combination of cytarabine and homoharringtonine. All patients in the different groups receive the same maintenance therapy ;Induction therapy with combination of arsenic trioxide and daunorubicin. After achieved CR, patients receive consolidation treatment with combination of cytarabine and daunorubicin or mitoxantrone. All patients in the different groups receive the same maintenance therapy. ;Induction therapy with combination of all-trans retinoic acid and homoharringtonine. After achieved CR, patients receive consolidation treatment with combination of cytarabine and homoharringtonine. All patients in the different groups receive the same maintenance therapy ;Induction therapy with combination of all-trans retinoic acid and daunorubicin. After achieved CR, patients receive consolidation treatment with combination of cytarabine and daunorubicin or mitoxantrone. All patients in the different groups receive the same maintenance therapy | Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Science; Level of the institution：, Self-finance | acute promyelocytic leukemia | | | | |
| Completed | 4 | 100 | | cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion, G-CSF (300 ug/d) by subcutaneous injection from day 0 until neutrophil count recovery to 2.0*10^9/L. | Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, SHDC12010202 | high-risk MDS and AML transformed from MDS | | | | |
ChiCTR-TRC-10001209: A Phase III Study on optimizing treatment for elderly patients with acute myeloid leukemia |
|
|
| Completed | 4 | 500 | | HA±G-CSF for induction therapy ;AA±G-CSF for induction therapy ;consolidation therapy after complete response without autologous stem cell ;consolidation therapy after complete response supported by autologous stem cell | Hospital of Blood Diseases, Chinese Academy of Medical Sciences; Ministry of Health, China, Ministry of Health funding | Elderly patients with acute myeloid leukemia | | | | |
ChiCTR-RCH-12002872: Expression of glucocorticoid receptor isforms and regulation mechanism in glucocorticoid-resistance lymphoid malignancies |
|
|
| Completed | 4 | 220 | | glucocorticoid treatment ;glucocorticoid treatment ;glucocorticoid treatment ;glucocorticoid treatment ;glucocorticoid treatment ;glucocorticoid treatment | Department of Hematology, the First Affiliated Hospital of Dalian Medical University; Department of Hematology, the First Affiliated Hospital of Dalian Medical University, self-funded | multiple myeloma;acute lymphocyte leukemia;non-hodgkin lymphoma | | | | |
2014-001561-27: Neuropathy caused by vincristine in children with leukemia: comparing one-hour infusions with short-term infusions Neuropathie door vincristine bij kinderen met leukemie: één-uurs infusen vergeleken met kortdurende infusies |
|
|
| Ongoing | 4 | 88 | Europe | Vincristine sulfate, Vincristine Sulphate, VCR, Solution for infusion, Solution for injection | VU university medical center, The Netherlands Organisation for Health Research and Development (in Dutch: ZonMw) | Pediatric oncology, acute lymphoblastic leukemia, nephroblastoma, medulloblastoma, low-grade glioma, Hodgkin lymphoma, rhabdomyosarcoma Kinderoncologie, acute lymfatische leukemie, nefroblastoom, medulloblastoom, laaggradig glioom, Hodgkin lymfoom en rhabdomyosarcoom, Childhood cancer Kinderkanker, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-ONC-14004845: The efficacy fety of Xinwei (Generic Imatinib) versus Glevic as the first line treatment in patients with newly diagnosed chronic-phase chronic myelogenous leukemia |
|
|
| Completed | 4 | 210 | | Domistic made imatinib ;Generic Imatinib | Peking University Peoples Hospital; Level of the institution：, Jiangsu Hansoh pharmaceutical | Chronic myelogenous leukemia | | | | |
ChiCTR-TRC-14004836: A single-center, randomized, clinical study of a single dose of peg-rhG-CSF compared with daily rhG-CSF for supporting neutrophil recovery in acute myeloid leukemia patients. |
|
|
| Not yet recruiting | 4 | 60 | | peg-rhG-CSF ;rhG-CSF | Institute of Hematology &Blood Disease Hospital, Chinese Academy of Medical Sciences; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, shiyao groups | acute myeloid leukemia | | | | |
2005-002782-37: A Randomised Trial of Inhaled Entonox Plus Local Anaesthesia Versus Intravenous Midazolam Plus Local Anaesthesia To Improve Pain Control During Bone Marrow Biopsy |
|
|
| Ongoing | 4 | 50 | Europe | Entonox, Midazolam, Entonox, Entonox 50% Oxygen/Nitrous Oxide, Midazolam, Entonox 50% Oxygen/Nitrous Oxide, Midazolam | Heart of England NHS Foundation Trust | This study will involve a group of patients requiring diagnostic bone marrow aspiration and biopsy. The reasons for these will include haematological abnormalities of the blood count , which may be caused by Leukaemia, lymphoma other related disorders. | | | | |
2005-003761-16: Evaluation of pneumococcal conjugate vaccine (Prevenar) in patients with myeloma and chronic lymphocytic leukaemia |
|
|
| Ongoing | 4 | 97 | Europe | PREVENAR, PNEUMOVAX II Vial, N/A, PREVENAR, Pneumovax II, PREVENAR, Pneumovax II | Department of R & D, Central Manchester and Manchester Children\'s Hospital NHS Trust | Pneumococcal disease is a common form of meningitis, septicaemia and pneumonia. Those individuals at highest risk include children, the elderly and persons whose immune systems are impaired. This latter group is diverse includes patients with the haematological disorders myeloma and chronic lymphocytic leukaemia in whom infections are a leading cause of death. | | | | |
2006-005195-40: Comparsion between articaine and lignocaine regional anaesthesian in patients undergoing bone marrow biopsy |
|
|
| Ongoing | 4 | 200 | Europe | Ultracain ohne Adrenalin 40 mg/ml, Xylocaine, Ultracain ohne Adrenalin 40 mg/ml, Xylocain 20 mg/ml, Ultracain ohne Adrenalin 40 mg/ml, Xylocain 20 mg/ml | Leila Niemi-Murola | Patients suffering from different forms of leukemia | | | | |
2006-000741-19: A phase I study of subcutaneous alemtuzumab in combination with oral fludarabine in previously untreated patients with chronic lymphocytic leukaemia. |
|
|
| Ongoing | 4 | 20 | Europe | MabCampath, Fludarabine, MabCampath, Fludara, MabCampath, Fludara | UHL NHS Trust | Chronic Lymphocytic Leukaemia (CLL) | | | | |
2008-006342-25: ADMIRE: Does the ADdition of Mitoxantrone Improve REsponse to FCR chemotherapy in patients with CLL: A randomised Phase II Trial of fludarabine, cyclophosphamide and rituximab (FCR) with or without mitoxantrone (M) in previously untreated chronic lymphocytic leukaemia |
|
|
| Ongoing | 4 | 218 | Europe | Rituximab (MabThera), Fludarbine (Fludara Oral), Fludarabine (Fludara), Cyclophosphamide Tablets, Cyclophosphamide injection, Mitoxantrone, MabThera, Mitoxantrone, MabThera, Mitoxantrone | Leeds Teaching Hospitals NHS Trust | Chronic Lymphocytic Leukaemia | | | | |
2009-010998-20: Attenuated dose Rituximab with ChemoTherapy In CLL:A randomised, phase IIB trial in previously untreated patients with Chronic Lymphocytic Leukaemia (CLL) tocompare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR) |
|
|
| Ongoing | 4 | 206 | Europe | Rituximab (MabThera), Fludarabine (Fludara Oral), Cyclophosphamide Tablets, Fludarabine (Fludara), Mitoxantrone, Rituximab (MabThera or Rituxan) (Reduced dose), Cyclophosphamide injection, MabThera, Mitoxantrone, MabThera, Mitoxantrone | Leeds Teaching Hospitals NHS Trust | Chronic Lymphocytic Leukaemia | | | | |
| Ongoing | 4 | 268 | Europe | Tostran 2% Gel, n/a, Tostran 2% Gel, Tostran 2% Gel | Sheffield Teaching Hospitals NHS Foundation Trust, Cancer Research UK, ProStrakan Ltd | Borderline low levels of testosterone in male cancer survivors who have previously had leukaemia, lymphoma or testicular cancer. | | | | |
ChiCTR-IPR-17011884: Multi center clinical study of the efficacy and safety of rhTPO in treatment of thrombocytopenia after chemotherapy for acute myeloid leukemia |
|
|
| Completed | 4 | 85 | | subcutaneously injection of recombinant human TPO ;blank | Shandong provincial hospital; Shandong provincial hospital, self-paying | Acute myeloid leukemia | | | | |
2015-003940-38: Study of posaconazole blood levels comparing two different oral presentations, a syrup and a solid tablet, in patients with leukaemia at a high risk of fungal infections Estudio de niveles de posaconazol en sangre comparando dos presentaciones del fármaco, una en jarabe y otra en tabletas, en pacientes con leucemia con alto riesgo de infecciones fúngicas |
|
|
| Ongoing | 4 | 20 | Europe | Oral suspension, Gastro-resistant tablet, Noxafil 40 mg/ml suspensión oral, Noxafil 100 mg comprimidos gastrorresistentes | Fundación Investigación Biomédica Puerta de Hierro, Merck Sharp & Dohme España | Invasive Mycoses Micosis invasoras, Severe fungal infections Infecciones graves por hongos, Diseases [C] - Bacterial Infections and Mycoses [C01] | | | | |
2007-000806-64: Sequential treatment with Cytoreductive therapy & transplant for Relapsed/ Refractory Acute Myeloid Leukemia, High Risk Myelodysplasia,or other High Risk Myeloid Malignancies |
|
|
| Ongoing | 4 | 93 | Europe | Daunorubicin, Cytarabine Injection Solution 100mg/ml, Fludarabine, Methotrexate, Cyclophosphamide, | Barts Health NHS Trust | Relapsed/ Refractory Acute Myeloid Leukemia, High Risk Myelodysplasia,or other High Risk Myeloid Malignancies | | | | |
| Ongoing | 4 | 120 | Europe | Prevenar-13, N/A, Prevenar-13, Prevenar-13 | University Hospital Southampton NHS Foundation Trust, NIHR | Childhood Acute Lymphoblastic Leukaemia | | | | |
2016-002372-27: Administration of blinatumomab to one pediatric patient Blinatumomab használata egy gyermek betegnél |
|
|
| Ongoing | 4 | 1 | Europe | BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion, Concentrate and solvent for solution for infusion, Blincyto | BAZ Megyei és Egyetemi Oktató Kórház, Amgen Kft. | B-precursor acute lymphoblastic leukaemia, acut lymphoid leukemia, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
ChiCTR-TRC-11001482: A randomised clinical trial to compare the efficacy and safety of IA and intensive DA regimen as induction chemotherapy for de novo acute myeloid leukemia (AML) patients |
|
|
| Recruiting | 4 | 240 | | Idarubicin 12mg/ m2, intravenously administration daily for 3 days; Cytarabine 100mg/ m2,intravenously administration (mentain 24 hours) daily for 7days ;Daunorubicin 90mg/ m2, intravenously administration daily for 3 days; Cytarabine 100mg/ m2,intravenously administration (mentain 24 hours) daily for 7days | The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, self-funded | acute myeloid leukemia (AML) | | | | |
ChiCTR-TRC-11001479: IA regimen as the induction chemotherapy in treatment of acute myeloid leukemia (AML): a multi-center, randomised clinical trial |
|
|
| Recruiting | 4 | 600 | | Idarubicin 8mg/ m2, intravenously administration daily for 3 days；Cytarabine 100mg/ m2,intravenously administration (mentain 24 hours) ;Idarubicin 10mg/ m2, intravenously administration daily for 3 days；Cytarabine 100mg/ m2,intravenously administration (mentain 24 hours) daily for 7days | the First Affiliated Hospital of Soochow University; the First Affiliated Hospital of Soochow University, self-funding | acute myeloid leukemia (AML) | | | | |
2016-001223-31: Incidence of Invasive Fungal Disease in Patients receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole tablet Prophylaxis |
|
|
| Ongoing | 4 | 150 | Europe | Noxafil Gastro resistant tablets, Tablet, Noxafil® | King's College Hospital NHS Foundation Trust, Merck Sharp & Dohme Limited (MSD). | Aplastic Anaemia, Myelodysplastic syndromes, Acute Myeloid Leukaemia undergoing immunosuppression therapy, high dose chemotherapy or reduced intensity stem cell transplantation, Fungal infection as a result of immunosuppressive therapy, chemotherapy or stem cell transplantation., Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2013-001639-38: Verification of the effectiveness of adding granulocyte stimulating factor (G-CSF) to therapy patients with myelodysplastic syndrome (MDS) in high-risk disease. Ověření účinností přidání granulocyty stimulujícího faktoru (G-CSF) k dosavadní terapii nemocných s Myelodysplastickým syndromem (MDS) ve vysokém riziku onemocnění. |
|
|
| Ongoing | 4 | 135 | Europe | AZACITIDINE 25 mg/ml, FILGRASTIM, Powder for suspension for injection, Solution for injection/infusion, AZACITIDINE 25 mg/ml (Vidaza), FILGRASTIM 30 MU (60 MU/ml) FILGRASTIM 48 MU (96 MU/ml) | 1st Dep. of Medicine, General University Hospital (VFN) in Prague, 1st Dep. of Medicine, General University Hospital in Prague (VFN) | Patients with the diagnosis:HR-MDS, AML less than 30% myeloblasts and CMML II, who will be treated with AZA or AZA + G-CSF. Pacienti s diagnózou: HR-MDS, AML do 30% myeloblastů a CMML II, které budou lečeny terapii AZA nebo AZA + G-CSF., High risk Myelodysplastic sy., Acute myeloid leukemia less than 30% myeloblasts and chronic myelomonocytic leukemia II, who will be treated with therapy Azacitidine or Azacitidine + G-CSF. Myelodysplastický syndrom s vysokým riskem, Akutní myeloidní leukemie do 30 % myeloblastů a Chronická myelomonocytární leukemie II, budou léčeny terapii Azacitidinem nebo Azacitidinem + G-CSF., Diseases [C] - Cancer [C04] | | | | |
ChiCTR-IPR-17011449: A novel drug administration Schedule of amphotericin B for childhood acute leukemia with Invasive Fungal Disease. |
|
|
| Completed | 4 | 108 | | 6 day slow dose escalation strategy (0.1-0.2-0.3-0.4-0.5-0.7mg/kg) of amphotericin B ;3 day slow dose escalation strategy (0.2-0.4-0.7mg/kg) of amphotericin B | Xiangya Hospital, Central South University; Xiangya Hospital, Central South University, National Natural Science Foundation of China | pediatric leukaemia | | | | |
ChiCTR-ONC-14004688: Clinical Trial of Therapy with Thalidomide、Interferon and Interleukin-2 in Refractory/relapsed and Elderly Acute Myeloid Leukemia |
|
|
| Recruiting | 4 | 100 | | thalidomide，interferon，interleukin-2 | The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital; None, self-financed | refractory/relapsed and elderly acute myeloid leukemia | | | | |
ChiCTR-IPR-17012643: Subcutaneous vs intravenous administration of cytarabine during inductive chemotherapy in patients with de-novo acute myeloid leukemia: a prospective, multicenter, randomized controlled clinical trial |
|
|
| Recruiting | 4 | 240 | | Subcutaneous administration of cytarabine; Intravenous administration of cytarabine | The First affiliated Hospital, School of Medicine, Zhejiang University; The First affiliated Hospital, School of Medicine, Zhejiang University, Department of Hematology, The First affiliated Hospital, School of Medicine, Zhejiang University | Acute Myelogenous Leukemia | | | | |
ChiCTR-IPR-16010006: An open-label, multicenter, prospective, Randomized Controlled Trial for Decitabine combined with arsenic trioxide and Ascorbic acid in subjects with Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts (MDS-RAEB) and Chronic Myelomonocytic Leukaemia (CMML) |
|
|
| Not yet recruiting | 4 | 260 | | Decitabine ;Decitabine combined with arsenic trioxide and Ascorbic acid | Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences | Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukaemia(CMML) | | | | |
| Ongoing | 4 | 800 | Europe | Obinutuzumab, Fludarabine, Fludarabine (IV), Cyclophospamide (oral), Cyclophosphamide (IV), Rituximab, Bendamustine, Mitoxantrone, Alemtuzumab, Ofatumumab, Concentrate for solution for infusion, Film-coated tablet, Powder for solution for infusion, Tablet, Powder for concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Obinutuzumab, Fludarabine (oral), Ofatumumab | University of Leeds, Napp Pharmaceuticals | Chronic lymphocytic leukaemia (CLL), Chronic lymphocytic leukaemia (CLL), Diseases [C] - Cancer [C04] | | | | |
ChiCTR-OPC-17010598: A multicenter, prospective study for lower dose Decitabine in subjects with Chronic Myelomonocytic Leukaemia (CMML) |
|
|
| Not yet recruiting | 4 | 30 | | Decitabine | Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Institute of Hematology and Blood Diseases Hospital , Chinese Academy of Medical Sciences | Chronic Myelomonocytic Leukaemia (CMML) | | | | |
MDS-DAC+RIF, ChiCTR-OPN-17011153: An open-label, multicenter, prospective, single-arm Trial for Decitabine combined with Realgar-Indigo natualis Formula (RIF) in subjects with Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts (MDS-RAEB) and Chronic Myelomonocytic Leukaemia (CMML) |
|
|
| Not yet recruiting | 4 | 140 | | Decitabine ;Realgar-Indigo natualis Formula | Department of Hematology, The First Affiliated Hospital, Zhejiang University; The First Affiliated Hospital, Zhejiang University, Research funding | Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts (MDS-RAEB) and Chronic Myelomonocytic Leukaemia (CMML) | | | | |
ChiCTR-IPR-15006071: Single site, randomized controlled clinical study of the efficacy and safety of rh TPO in treatment of thrombocytopenia after chemotherapy for children acute lymphoblastic leukemia |
|
|
| Not yet recruiting | 4 | 144 | | TPO 300 U/kg ,subcutaneous injection once daily, period of treatment is equal to or less than 14 days. If the platelet count >50*10^9 / L, test two times continuously(not the same day),less than 14 days, or the platelet count increased absolute value is more than 30*10^9/L, stop using TPO ;Blank | The Children's Hospital of Zhejiang University School of Medicine; The Children's Hospital of Zhejiang University School of Medicine, Shenyang sunshine pharmaceutical CO..LTD | acute lymphoblastic leukemia | | | | |
ChiCTR-OPC-17011225: Efficacy and safety of DAC-CAG regimen: an open-label, prospective study in the primary elderly acute myeloid leukemia |
|
|
| Not yet recruiting | 4 | 80 | | DAC-CAG regimen | Department of Hematology, Tangdu Hospital, Fourth Military Medical University; Level of the institution：, This project is supported by the innovation and development fund of Tangdu Hospital | acute myeloid leukemia | | | | |
ChiCTR-OPC-16010166: Efficacy and safety of cladribine in combination with G-CSF, low-dose cytarabine and aclarubicin in patients with refractory/relapsed acute myeloid leukemia: a phase 2, single center, single arm study |
|
|
| Recruiting | 4 | 30 | | cladribine in combination with G-CSF, low-dose cytarabine and aclarubicin | Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Sun Yat-sen University Cancer Center | acute myeloid leukemia | | | | |
ChiCTR-TRC-14004196: Haplo-mismatch Donor Stem Cell Transplantation (SCT) versus Autologous SCT followed or not by maintenance therapy, for Patients with Acute Myeloid Leukemia (AML) in First Remission: A Chinese Randomized Multicenter Study |
|
|
| Recruiting | 4 | 212 | | undergo haplo-SCT ;undergo ASCT | Department of Hematology, the First Affiliated Hospital of Soochow University; Department of Hematology, the First Affiliated Hospital of Soochow University, Supported by Jiangsu Province’s Key Medical Center (ZX201102); National Public Health Grand Research Foundation (No.201202017); National High-tech R&D Program (863 Program) (2012AA02A505） | Acute Myeloid Leukemia | | | | |
ChiCTR-IIR-16008809: Homoharringtonine, aclacinomycin, cyctarabine and G-CSF (HCAG) regimen in the treatment of newly diagnosed elderly acute myeloid leukemia |
|
|
| Recruiting | 4 | 404 | | DA regimen ;HCAG regimen | Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Institute of Hematology; Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine, Self-financing | Acute myeloid leukemia | | | | |
| Recruiting | 4 | 800 | | DAH induction+ATRA maintenance ;DAE induction+ATRA maintenance ;DAH induction+Ara-c maintenance ;DAE induction+Ara-c maintenance | Capital Medical University Beijing Children’s Hospital; Capital Medical University Beijing Children’s Hospital, Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding | pediatic acute myeloid leukemia | | | | |
ChiCTR1800015763: Dasatinib for Treatment of de novo Ph-Positive Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 4 | 100 | | dasatinib | West China Hospital of Sichuan University; Dazhou Central Hospital, Self-raised | Ph-positive acute lymphoblastic leukemia | | | | |
ChiCTR-RPC-16010078: The influence of polymorphisms of metabolic enzymes and transporters on pharmacokinetics and clinical response to imatinib, dasatinib and nilotinib |
|
|
| Recruiting | 4 | 450 | | The determination of concentration and genotypes ;The determination of concentration and genotypes ;The determination of concentration and genotypes | The Second Xiangya Hospital of Central South University; The Second Xiangya Hospital of Central South University, raise (funds/etc.) independently | chronic myelogenous leukemia | | | | |
ChiCTR1800015871: A clinical study of chidamide with FLAG (fludarabine+cytarabine+G-CSF) in the treatment of relapsed /refractory /first cycle induced non-remission acute myeloid leukemia |
|
|
| Recruiting | 4 | 10 | | Chidamide | Anhui Provincial Hospital; Anhui Provincial Hospital, chipscreen | Acute myeloid leukemia | | | | |
ChiCTR-OCH-14004731: Sorafenib in the treatment of AML patients with FLT3-ITD mutation: a cohort study |
|
|
| Recruiting | 4 | 100 | | Sorafenib ;Sorafenib ;Sorafenib ;Sorafenib ;Sorafenib | Department of Hematology, the First Affiliated Hospital of Soochow University; The First Affiliatd Hospital of Soochow University, None | Acute Myeloid Leukemia | | | | |
ChiCTR1800015307: To predict the therapeutical effect and adverse reaction of methotrexate based on Metabonomics |
|
|
| Recruiting | 4 | 160 | | Nil | Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital; Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Youth fund of Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital | Acute lymphoblastic leukemia | | | | |
2019-000661-20: Cancer treatment with anthracyclines may cause heart damage and can lead to heart failure. There are drugs which may protect against cardiotoxic effects of anthracyclines, but they are untolerated due to hypotension. Ivabradine is heart rate lowering drug without effect on blood pressure which was approved for treatment of angina pectoris and heart failure. The aim of this study is to investigate protective effects of ivabradine in cancer patients undergoing anthracycline-based chemotherapy. Chemoterapija antraciklinais sukelia širdies raumens pažeidimą. Siekiant to išvengti yra skiriami vaistai, bet jie nepakankamai veiksmingi ir turi nepageidaujamų reiškinių. Ivabradinas yra vaistas, skirtas krūtinės angina ir lėtiniu širdies nepakankamumu sergantiems pacientams, kuris mažina pulsą nemažindamas kraujospūdžio. Tyrimo tikslas yra nustatyti, ar ivabradinas saugus ir veiksmingas vėžiu sergantiems ir antraciklinais gydomiems pacientams. |
|
|
| Not yet recruiting | 4 | 150 | Europe | Ivabradine Anpharm 7,5 mg, Film-coated tablet, Ivabradine Anpharm 5 mg, Ivabradine Anpharm 7,5 mg | Vilnius University Hospital Santaros klinikos, Society of cardiovascular medicine | Cancers treated with anthracyclines: leukemias, limphomas, breast, stomach, uterine, ovarian, lung. Vėžiniai susirgimai gydomi antraciklinų grupės preparatais: leukemijos, limfomos, krūties, skrandžio, gimdos, kiaušidžių, plaučių., Cancer: blood, lymphnode, breast, stomach, uterine, ovarian, lung. Vėžys: kraujo, limfmazgių, krūties, skrandžio, gimdos, kiaušidžių, plaučių., Diseases [C] - Cancer [C04] | | | | |
ChiCTR-OPC-17011617: A multicenter, prospective study for ultra low-dose decitabine in elderly patients with acute myelocytic leukemia or intermediate-high risk myelodysplastic syndrome |
|
|
| Not yet recruiting | 4 | 40 | | ultra low-dose decitabine | Central Hospital of Anshan City, The sixth clinical college of China Medical University; Central Hospital of Anshan City, The sixth clinical college of China Medical University, self-funding | acute myelocytic leukemia or myelodysplastic syndrome | | | | |
ChiCTR-IPR-17011619: A multicenter, prospective, double arm clinical study for ultra low-dose decitabine combined with compound preparation of As4S4 in patients with intermediate-high risk myelodysplastic syndrome |
|
|
| Not yet recruiting | 4 | 60 | | decitabine ;decitabine combined with compound preparation of As4S4 | The General Hospital of Shenyang Military; Central Hospital of Anshan City, The sixth clinical college of China Medical University, Central Hospital of Anshan City,The sixth clinical college of China Medical University | myelody splastic syndromes or chronic myelomonocytic leukemia | | | | |
ChiCTR-OIC-16008952: The clinical study of initial induced remission failure in elderly patients with acute myeloid leukemia treated by IA in combination with decitabine |
|
|
| Not yet recruiting | 4 | 50 | | Decitabine+IA | Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine; Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine, QILU pharmaceutical co.,Ltd. | Acute myeloid leukemia | | | | |
2019-004295-18: Fibrinogen and platelets in patients with acute myeloid leukaemia and thrombocytopenia |
|
|
| Ongoing | 4 | 20 | Europe | Concentrate for solution for infusion, Riastap | Aarhus University Hospital, Kræftens Bekæmpelse, CSL Behring | Bleeding i patients with acute myeloid leukemia, Bleeding i patients with acute myeloid leukemia, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
ChiCTR-OIN-16007780: Efficacy and safety of conditioning including idarubicin and antithymocyte globulin in sibling donor allogeneic hematopoietic stem cell transplantation for standard-risk acute leukemia |
|
|
| Recruiting | 4 | 30 | | conditioning including idarubicin and antithymocyte globulin | The First Affilited Hospital of Guangxi Medical University; The First Affilited Hospital of Guangxi Medical University, self-financing | Acute leukemia | | | | |
| Recruiting | 4 | 300 | | ATRA+ATO/RIF ;ATRA+ATO/RIF+CT | Capital Medical University Beijing Children's Hospital; Capital Medical University Beijing Children’s Hospital, none | childhood acute promyelocytic leukemia | | | | |
ChiCTR-OPC-16009670: A multicenter study of precise treatment for children with acute promyelocytic leukemia |
|
|
| Recruiting | 4 | 200 | | treatment regimen for low risk group patients ;treatment regimen for high risk group patients | Children's Hospital of Shanghai; Children’s Hospital of Shanghai, Shanghai hospital development center and Children's Hospital of Shanghai | Acute Promyelocytic Leukemia | | | | |
ChiCTR-IPR-16009917: Comparison of the curative efficacy and safety of allo-HSCT by using conditioning regiment of modified BUCY or CLAG combined with modified BUCY for refractory and relapsed patients with acute myelocytic leukemia: a sigle-center prospective randomized controlled clinical trial |
|
|
| Not yet recruiting | 4 | 116 | | Modified BUCY ;GLAG combined with BUCY | Aerospace Center Hospital; Aerospace Center Hospital, Beijing Municipal Science and Technology Commission | Relapse and Refractory Acute Myelocytic Leukemia | | | | |
ChiCTR-OPN-17012796: The single center, prospective clinical trial of low-dose Decitabine in the treatment of MDS/AML early relapse after allogeneic hematopoietic stem cell transplantation |
|
|
| Recruiting | 4 | 40 | | decitabine 5mg/m2 d1-5 | Department of Hematology, Xinqiao Hospital, Military Medical University; Xinqiao Hospital, Clinical Founding of Xinqiao Hospital | acute myeloid leukemia/Myelodysplastic syndrom | | | | |
ChiCTR-TRC-13004021: A Multicenter and Randomized Prospective Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia |
|
|
| Recruiting | 4 | 240 | | ATO+ATRA+chemotherapy ;RIF+ATRA+chemotherapy | The First Affiliated Hospital of Sun Yat-Sen University; Level of the institution：, Sun Yat-Sen University | Childhood Acute Promyeloid Leukemia | | | | |
ChiCTR-IPR-17011239: efficacy of prophylactic Levofloxacin for prevention of gut infection among de-novo AML patients: a randomised study |
|
|
| Recruiting | 4 | 120 | | prophylactic Levofloxacin ;no prophylactic antibiotics | Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Institute of Hematology; Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine, self-financing | Acute myeloid leukemia | | | | |
ChiCTR1900023025: Clinical study for rhTPO in the treatment of thrombocytopenia after chemotherapy for acute leukemia |
|
|
| Not yet recruiting | 4 | 60 | | subcutaneously injection of recombinant human TPO ;blank | Anhui Provincial Hospital; Anhui Provincial Hospital, Self-financing | thrombocytopenia after chemotherapy for acute leukemia | | | | |
ChiCTR1800016277: Pretreatment of bone marrow transplantation was used to treat the efficacy and safety of Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). |
|
|
| Recruiting | 4 | 20 | | All patients who met the criteria were treated with the Dashatinib combined bone marrow transplantation pretreatment program to monitor the BCR-ABL fusion gene quantification before and after transplantation. | Affiliated Hospital of Dalian Medical University; Affiliated Hospital of Dalian Medical University, self-paying | Ph+ acute lymphoblastic leukemia | | | | |
ChiCTR1800016691: Clinical research of Decitabine combined reduction FLAG regimen in the treatment of previously untreated high-risk and refractory or relapsed aged patients with acute myeloid leukemia |
|
|
| Not yet recruiting | 4 | 200 | | Decitabine combined reduction FLAG regimen ;Decitabine combined reduction FLAG regimen | Tianjin First Center Hospital; Tianjin First Center Hospital, Tianjin health department and Tianjin First Center Hospital | Acute myeloid leukemia | | | | |
2020-002850-26: Immune response test as new predictor for successful TKI stop in patients with chronic myeloid leukemia Immuunresponstest als nieuwe voorspeller voor succesvolle TKI-stop bij patiënten met chronische myeloïde leukemie. |
|
|
| Not yet recruiting | 4 | 57 | Europe | Solution for injection, PNEUMOVAX 23 | Albert Schweitzer Hospital, Albert Schweitzer Hospital | Chronic myeloid leukemia, Chronic myeloid leukemia is a cancer of the white blood cells and is characterized by an overgrowth of these cells in the bone marrow and the accumulation of these cells in the blood., Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT02926586: Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML |
|
|
| Recruiting | 4 | 200 | RoW | Fludarabine, Fludara, Cytarabine, Cytosar | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Acute Myeloid Leukemia, Core-Binding Factor | 08/20 | 07/24 | | |
ChiCTR-OPC-17010755: Tyrosine Kinase Inhibitor Discontinuation in Adults Patients with Chronic Myeloid Leukaemia in China |
|
|
| Not yet recruiting | 4 | 98 | | Tyrosine Kinase Inhibitor | The First Affiliated Hospital of Shenzhen University; The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen Municipal Government of China | Chronic Myeloid Leukaemia | | | | |
ChiCTR1800020372: A multicenter, one-arm, open, prospective study for Decitabine combined with CHAG + cidabenamine in the treatment of relapsed/refractory acute myeloid leukemia (AML) |
|
|
| Recruiting | 4 | 50 | | Decitabine: 15mg/m2 intravenous d2-5 aclaramycin: 20mg/d intravenous administration qod d6, a total of 4-8 doses of harringtonine: 1mg/m2 intravenous administration qd d6-13 Cytarabine: 15mg/m2 Subcutaneous administration q12h d6-19 G-CSF: 300ug/d subcutaneous injection of d6--neutrophil recovery (suspended when WBC?20×109/L) Sidabenamine: d1 | Henan Cancer Hospital; Henan Cancer Hospital, Self-financing | Relapsed/refractory acute myeloid leukemia | | | | |
ChiCTR1800019603: An open label, multicenter, randomized controlled trial for decitabine in combination with half dose of CAG regimen (D-CAG regimen) in the treatment of MDS-EB and AML-MRC compared with CAG regimen |
|
|
| Recruiting | 4 | 140 | | Decitabine in combination with half dose of CAG regimen. ;CAG scheme | People's Hospital, Institute of hematology, Peking University; Peking University People's Hospital, Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Myelodysplastic syndrome with excess blasts and Acute myeloid leukemia with myelodysplasia-related changes | | | | |
| Recruiting | 4 | 200 | | ATRA+ATO/RIF ;ATRA+ATO/RIF+chemotherapy | Beijing Children's Hospital, Capital Medical University; Beijing Children's Hospital， Capital Medical University, National Science and Technology Major Project | childhood acute promyelocytic leukemia | | | | |
ChiCTR1800019896: Effect of FOXO1 and PXR on drug resistance of imatinib in chronic myeloid leukemia |
|
|
| Recruiting | 4 | 200 | | Determination of BCR-ABL fusion gene IS value<=0.1% ;Determination of BCR-ABL fusion gene IS value>0.1% | The Second Xiangya Hospital of Central South University; the Second Xiangya Hospital, Central South University, raise (funds/etc.) independently | chronic myeloid leukemia | | | | |
| Not yet recruiting | 4 | 70 | | GCSF 300ug d0-d5, Cladribine 5mg/m2, d1-5, cytarabine 2g/m2 qd, d1-5, homoharringtonine 2mg/m2d1-d5. ;GCSF 300ug d0-d5, azacytidine 100mg, d1-5, cedarabine 10mg qd, d1-28, cytarabine 10mg/m2 q12h, d3-9, homoharringtonine 1mg d3-d9. | Sichuan People's Hospital; Sichuan People's Hospital, Sichuan Science and Technology Department | Acute myeloid leukemia | | | | |
ChiCTR2100041760: Pharmacokinetics and pharmacokinetics of recombinant human interferon alpha 2B for injection in healthy subjects |
|
|
| Recruiting | 4 | 8 | | The intervention should read, "Injection of recombinant human interferon alpha 2B subcutaneously at 2 million IU per dose, one dose. | Nanning First People's Hospital; Changchun Biological Products Research Institute Co. LTD, Changchun Biological Products Research Institute Co. LTD | For the treatment of some viral diseases, such as acute and chronic viral hepatitis, herpes zoster, condyloma acuminatum;For the treatment of certain tumors, such as hair cell leukemia, chronic myeloi | | | | |
ChiCTR1900021030: Clinical research for decitabine in maintenance therapy for intermediate/high-risk myelodysplastic syndrome and elderly acute myeloid leukemia. |
|
|
| Not yet recruiting | 4 | 40 | | Decitabine | The First Hospital of Lanzhou University; The First Hospital of Lanzhou University, Company sponsorship and research funding. | Myelodysplastic syndrome, Elderly acute myeloid leukemia | | | | |
2021-001107-33: SARS-CoV-2 vaccination response in patients with haematologicaldisease Respons op SARS-Cov-2 vaccinatie in patiënten met een hematologischeziekte |
|
|
| Ongoing | 4 | 743 | Europe | Comirnaty, Suspension for injection in pre-filled injector, Comirnaty | MUMC, MUMC | multiple myeloma (including MGUS)chronic lymphocytic leukemia, chronic myeloid leukemia, acute myeloidleukemia, acute lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkinlymphoma, myelodysplastic syndrome, myeloproliferative disease), haematological disease defined as:MM, MGUS, CLL, CML, AML, ALL, NHL, HL, MDS, MPN, Body processes [G] - Immune system processes [G12] | | | | |
NCT02670564: ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) |
|
|
| Recruiting | 4 | 1000 | Europe | Pharmacogenomics, DNA analyses, Busulfan plasma level measurements | Swiss Pediatric Oncology Group, ALL SCTped Forum | Acute Lymphoblastic Leukemia | 04/21 | 04/26 | | |
ChiCTR-TNC-10000955: Imatinib mesylate versus allogeneic HSCT for patients with chronic myelogenous leukemia |
|
|
| Completed | 4 | 600 | | transplant ;imatinib | People's Hospital, Peking University; Ministry of Education, China, National Outstanding Yong Scientists' Foundation of China, Program for Innovative Research Team in University and Beijing Novartis Pharma Co., Ltd., China | chronic myelogenous leukemia | | | | |
ChiCTR1900022613: The clinical study for Dasatinib and Homoharringtonine in treating CBF AML |
|
|
| Not yet recruiting | 4 | 550 | | conventional intensive chemotherapy ;conventional intensive chemotherapy+HHT | Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Institute of Hematology; Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Self-financing | Acute myeloid leukemia | | | | |
NCT05316831: Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia |
|
|
| Completed | 4 | 77 | Europe | PCV13, Prevenar13, PPSV23, Pneumovax23 | Region Örebro County | CLL, Vaccine Response | 06/21 | 10/22 | | |
| Recruiting | 4 | 60 | | Yinishu (dasatinib)70mg/d ;Yinishu (dasatinib)100mg/d | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Zhengda Tianqing company | Chronic myeloid leukemia | | | | |
ChiCTR1900026095: Venetoclax + azacitidine combined with dose-adjusted HAG double induction therapy for relapsed/refractory acute myeloid leukemia |
|
|
| Not yet recruiting | 4 | 10 | | Venetoclax + Azacitidine +HAG | The People's Hospital of Jiaozuo City; The People's Hospital of Jiaozuo City, Beijing Medical Award Foundation | Relapse/Refractory Acute Myeloid Leukemia | | | | |
ChiCTR1800016423: A non-interventional, observational post-marketing registry of Vidaza (subcutaneous azacitidine) in patients with intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia with 20-30 % blasts and multi-lineage dysplasia in China |
|
|
| Recruiting | 4 | 300 | | Vidaza | Tianjin Hematonosis Hospital; Tianjin Hematonosis Hospital, Celgene Pharmaceutical (Shanghai) Co. Ltd | Intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia with 20-30 % blasts and multi-lineage dysplasia | | | | |
ChiCTR1900023581: A prospective, single-arm, multicenter, phase II trial to evaluate the efficacy and safety of CAG regimen for relapse/refractory T-acute lymphocytic leukemia/T-lymphoblastic lymphoma |
|
|
| Not yet recruiting | 4 | 32 | | CAG regimen | The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, None | T-acute lymphocytic leukemia/ T-lymphoblastic lymphoma | | | | |
ChiCTR1900023368: Decitabine combined with conventional chemotherapy improves outcome in pediatric AML: a randomized controlled trial |
|
|
| Recruiting | 4 | 40 | | Decitabine and conventional chemotherapy ;conventional chemotherapy | The Seventh Affiliated Hospital, Sun Yat-sen University; The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen Manicipal Health Commission | Acute myeloid leukemia | | | | |
ChiCTR2000039224: Reserch on switching to flumatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) |
|
|
| Recruiting | 4 | 110 | | Take flumatinib regularly | The Hematology Department of the Second Affiliated Hospital of the Army Medical University; The Hematology Department of the Second Affiliated Hospital of the Army Medical University, self-raised | chronic myeloid leukemia | | | | |
2021-000722-96: changes in lymph nodes in patients with CLL treated with venetoclax-containing regimens Modificazioni del microambiente linfonodali in pazienti con leucemia linfatica cronica CLL in trattamento con regimi contenenti venetoclax |
|
|
| Not yet recruiting | 4 | 30 | Europe | Venclyxto, [Venclyxto], Coated tablet, venclyxto | OSPEDALE SAN RAFFAELE, AbbVie | Chronic Lymphocytic Leukemia Leucemia Linfatica Cronica, Chronic Lymphocytic Leukemia Leucemia Linfatica Cronica, Diseases [C] - Cancer [C04] | | | | |
2019-001585-15: PTX3 genetically stratified randomized double-blinded allocation event-driven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia Etude d’allocation génétique de la prophylaxie antifongique chez les patients traités pour une leucémie aiguë myéloïde |
|
|
| Ongoing | 4 | 105 | Europe | Solution for infusion, Powder for solution for infusion, Capsule, Tablet, Noxafil, Diflucan | Centre Hospitalier Universitaire Vaudois, Swiss National Science Foundation | Invasive mold infections leucémie aigue myéloïde, Invasive mold infections leucémie aigue myéloïde, Not possible to specify | | | | |
2021-006581-20: A patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia |
|
|
| Not yet recruiting | 4 | 106 | Europe | Tablet, Capsule, hard, Imatinib, SPRYCEL, Bosulif, Tasigna, Iclusig | Radboud univeristy medical centre, ZonMw | Chronic myeloid leukaemia, Blood cancers, leukaemia, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
ChiCTR2000040558: Reserch on switching to Flumatinib in patients with chronic myeloid leukemia who have not achieved an optimal response or intolerance after first-/second-line TKI therapy：A prospective, multicenter, observational study |
|
|
| Not yet recruiting | 4 | 150 | | none | The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, self-raised | chronic myeloid leukemia | | | | |
ChiCTR1900023805: Study for the role of pegaspargase, cyclophosphamide, demethyl daunorubicin, vindesine and dexamethasone in inducion remission of adults Ph negative acute lymphoblastic leukemia |
|
|
| Not yet recruiting | 4 | 146 | | Protocol of pegaspargase, cyclophosphamide, demethyl daunorubicin, vindesine and dexamethasone ;Protocol of pegaspargase, cyclophosphamide, daunorubicin, vindesine and dexamethasone | Medical Center of Hematology, Xinqiao Hospital of Army Medical University; Xinqiao Hospital, Army Medical University, This study was funded by the clinical key foundation of Xinqiao Hospital of Army Medical University | Adults Ph negative acute lymphoblastic leukemia | | | | |
ChiCTR2000034270: Flumatinib combined with autologous transplantation versus Dasatinib combined with autologous transplantation in the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia |
|
|
| Recruiting | 4 | 90 | | Flumatinib 600mg Po qd ;Dasatinib 70mg po bid | Affiliated Hospital of Southwest Medical University; Affiliated Hospital of Southwest Medical University, pharmaceutical factory | Philadelphia chromosome positive acute lymphoblastic leukemia | | | | |
ChiCTR2000037928: Clinical efficacy and MRD monitoring of relapse prevention of decitabine containing induction chemotherapy in de novo AML: a multi-center, prospective, randomized controlled study |
|
|
| Recruiting | 4 | 122 | | decitabine+IA chemotherapy ;IA chemotherapy | Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of science and technology; Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of science and technology, Self finance | Acute myeloid leukemia | | | | |
| Recruiting | 4 | 40 | RoW | Cyclosporine Ophthalmic, Ikervis | Singapore Eye Research Institute | Leukemia (Both ALL and AML), MDS-EB-1 | 08/22 | 12/22 | | |